Bevacizumab Approved Naked monospecific

Antibody Information

Entry ID	133
INN	Bevacizumab
Status	Approved
Drug code(s)	RHU-MAB-VEGF
Brand name	Avastin
mAb sequence source	mAb humanized
General Molecular Category	Naked monospecific
Format, general category	Full length Ab
Format details	None
Isotype (Fc)	IgG1
Light chain isotype	kappa
Linker	None
Ave. DAR	None
Conjugated/fused moiety	None
Discovery method/technology	None

Therapeutic information

Target(s)	VEGF
Indications of clinical studies	Renal Cell Carcinoma, colorectal, breast cancer
Primary therapeutic area	Cancer

Development stage information

Phase lengths*

*The graph represents early-stage clinical development phase lengths. For molecules approved or under evaluation for marketing authorization in the US is provided a complete overview of all clinical development phase lengths. Phase lengths are calculated from the start of the first in human (FIH) study (Start of clinical phase). “Start of Phase 2” bar represents Phase 1 length (Start of clinical phase to start of Phase 2); “Start of Phase 3” bar represents Phase 1+2 length (Start of clinical phase to start of Phase 3); “Date BLA/NDA submitted” bar represents Phase 1+2+3 length (Start of clinical phase to Date BLA/NDA submitted); and “Date of first US approval” bar represents Phase 1 to first US approval length (Start of clinical phase to Date of first US approval).

Most advanced stage of development (global)	Approved EU, US, Japan, Australia
Status	Active
Start of clinical phase (IND filing or first Phase 1)	July 02, 1996
Start of Phase 2	May 15, 1998
Start of Phase 3	April 15, 2000
Date BLA/NDA submitted to FDA	September 30, 2003
Year of first approval (global)	2004
Date of first US approval	February 26, 2004
INN, US product name	Bevacizumab
US or EU approved indications	Non-Small Cell Lung Cancer, Renal Cell Cancer, Ovarian Cancer, Brain Cancer (Malignant Glioma; AA and GBM), Colorectal Cancer, Cervical Cancer, Breast Cancer; bevacizumab/carboplatin/paclitaxel treatment of stage III/IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection

Description/comment

None

Additional information

Anticipated events	None
Factor(s) contributing to discontinuation	None

Company	Genentech
Licensee/Partner	Bristol Myers Squibb, Merck
Comments about company or candidate	None
Full address of company	South San Francisco, California, United States North America United States of America https://www.gene.com/contact-us/visit-us